Article Text

PDF
086
REAL-WORLD DATA ON IMPACT OF ESLICARBAZEPINE ACETATE ON QOL
  1. Rob McMurray1,
  2. Michael Kerr2,
  3. Rui Sousa3,
  4. Martin Holtkamp4
  1. 1 Eisai Europe Ltd, UK
  2. 2 Cardiff University
  3. 3 Bial, Portugal
  4. 4 Charité – Universitätsmedizin Berlin, Germany

Abstract

Purpose To assess impact of eslicarbazepine acetate (ESL) on patient-rated quality of life (QOL) and clinician-rated global improvement in patients included in the EPOS (Eslicarbazepine acetate in Partial-Onset Seizures) study.

Method EPOS was an open-label, prospective study which included adults with uncontrolled partial-onset seizures receiving antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy. QOL was assessed (at baseline and after 3 and 6 months) using the QOL in Epilepsy Inventory-10 (QOLIE-10). Global improvement was assessed (after 3 and 6 months) using the Clinical Global Impression-Global Improvement scale (CGI-GI).

Results Overall, 219 patients were included in the study (mean age 45.9 years; 57.5% male). Complete QOLIE-10 data were available for 109 patients. Mean QOLIE-10 score decreased from 2.9 (n=128) at baseline to 2.4 (−14.6%; n=114) after 3 months and 2.1 (−20.8%; n=109) after 6 months. The majority of patients were ‘much improved’ or ‘very much improved’ on the CGI-GI after 3 months (‘much improved’, 49.8%; ‘very much improved’, 14.9%; n=211) and 6 months (‘much improved’, 41.7%; ‘very much improved’, 33.9%'; n=192).

Conclusion In this real-world study, ESL as add-on to antiepileptic monotherapy provided beneficial effects on patient-rated QOL and clinician-rated global improvement.

Supported by Eisai.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.